SCHEDULE 13D: Activist Investors Chaim Herzog and 111 Equity Group Take 5.17% Stake in Matinas Biopharma, Seek Strategic Alternatives Amidst Company Winddown Considerations

Chaim Herzog and 111 Equity Group LLC have disclosed a 5.17% beneficial ownership stake in Matinas Biopharma Holdings, Inc., intending to engage with management on strategic alternatives including asset sales, reverse mergers, or dissolution, following the company's cessation of product development.

Summary

• Chaim Herzog and 111 Equity Group LLC collectively own 263,000 shares, representing 5.17% of Matinas Biopharma Holdings, Inc.'s common stock.
• This stake was acquired through open market purchases using personal and working capital funds.
• The filing follows Matinas Biopharma's October 31, 2024, Current Report, which disclosed the termination of negotiations for its MAT2203 product candidate, workforce reduction, cessation of product development, and consideration of asset sale, winddown, or dissolution.
• The Reporting Persons intend to engage in discussions with Matinas management, the board, and other shareholders to explore options such as asset sale, exit sale, reverse merger, or other alternatives to enhance stockholder value.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to Matinas Biopharma's severe operational challenges, including the cessation of product development and consideration of winddown/dissolution. While the activist investor's involvement offers a glimmer of hope for value extraction, the underlying company situation is dire.

Positives

• An activist investor group, Chaim Herzog and 111 Equity Group, has taken a significant 5.17% stake, indicating a belief in potential value.
• The Reporting Persons intend to actively engage with management and the board to explore strategic alternatives, including asset sales or reverse mergers, which could potentially unlock value for shareholders.

Negatives

• Matinas Biopharma has terminated negotiations for global rights to its key product candidate, MAT2203.
• The company has reduced its workforce and ceased all product development activities to conserve cash.
• Matinas Biopharma is evaluating severe alternatives, including the potential winddown and dissolution of the Issuer.

Risks

• The Issuer may proceed with a winddown and dissolution, potentially leading to significant loss of shareholder value.
• There is no assurance that an advisor will be successfully retained or that a suitable buyer for the MAT2203 asset will be found.
• Strategic alternatives like reverse mergers or exit sales may not materialize or may not be favorable to existing shareholders.
• The Reporting Persons may change their investment intent, including selling their shares, which could negatively impact the stock price.

Future Outlook

The Reporting Persons intend to engage in discussions with Matinas Biopharma's management, board of directors, and other shareholders to evaluate and propose strategic alternatives aimed at enhancing stockholder value, including potential asset sales, exit sales, reverse mergers, or other options, while retaining the right to change their investment intent.

Management Comments

• The filing references Matinas Biopharma's Current Report filed on October 31, 2024, which stated the Issuer's intent to retain an advisor for a potential asset sale of MAT2203 and to evaluate other alternatives, including winddown and dissolution.

Industry Context

This filing highlights the significant challenges faced by small biopharmaceutical companies, particularly after the failure or termination of key product development programs. The company's move to cease development and consider winddown or asset sales is a common, albeit drastic, measure to conserve capital and potentially return value to shareholders in such circumstances. The entry of an activist investor suggests a belief that there is still underlying value to be unlocked, potentially through strategic transactions rather than continued operations.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for value enhancement if strategic alternatives are successfully executed, or significant loss if the company proceeds with winddown/dissolution.
• Employees: Workforce reduction has already occurred, indicating negative impact on employees.
• Creditors: Potential impact depending on the outcome of asset sales or dissolution proceedings.

Next Steps

• Reporting Persons intend to engage in discussions with Matinas Biopharma management, board of directors, and other shareholders.
• Reporting Persons may propose changes in the Issuer's operations, governance, or capitalization.
• Reporting Persons may modify their ownership of shares, including purchases or sales.
• Matinas Biopharma intends to retain an advisor to assist with potential asset sale of MAT2203 and evaluate other alternatives.

Key Dates

Recommendation

Keywords

Matinas Biopharma, Schedule 13D, Chaim Herzog, 111 Equity Group, activist investor, MAT2203, asset sale, reverse merger, winddown, dissolution, biopharmaceutical, corporate governance, shareholder value